Transmedics (TMDX) Market Update
- Price movement: The Transmedics stock closed down 3.14 % during the 24‑hour period ending at 08:14 PM Central Europe on Friday, 23 November 2026.
- Current price: The share is trading at USD 71.81 on major exchanges.
- Shares outstanding: 34.7 million.
- Market capitalization: USD 2.5 billion.
- Trading volume (last 24 h): USD 49.6 million worth of shares were exchanged.
- Month‑end performance: The stock has declined 17.79 % since the end of October 2026.
- 200‑day moving average: USD 96.88.
- 52‑week range: Highest price of USD 156.00 was reached on 12 February 2025; the lowest price of USD 60.10 was recorded on 13 May 2026.
Upcoming Corporate Events
TransMedics Group Inc., a medical‑technology firm focused on organ transplant solutions, has announced that it will release its third‑quarter 2026 financial results after the market close on 5 November 2026.
- Conference call: Scheduled for 4:30 p.m. Eastern Time.
- Access: Participants can join by telephone or via webcast on the company’s investor website.
- Headquarters: Andover, Massachusetts.
- Product focus: The company is developing portable systems that warm and assess donor organs prior to transplantation, aiming to improve organ quality and availability for patients with severe heart, lung, or liver failure.
Related Stock Performance (Last 24 Hours)
| Ticker | % Change | Current Price | Market Cap (USD) | P/E Ratio |
|---|---|---|---|---|
| FRPT | +7.06 % | USD 64.33 | USD 3 bn | 17.21 |
| BKU | +3.99 % | USD 43.53 | USD 3 bn | 11.37 |
| DYN | –1.23 % | USD 15.49 | USD 3 bn | – |
| DNLI | –0.11 % | USD 18.29 | USD 3 bn | – |
| CELC | +6.51 % | USD 65.41 | USD 3 bn | – |
Additional Notes
- BankUnited (BKU): Shares have risen following the announcement of new strategic initiatives. The company’s management highlighted progress in expanding its service portfolio and strengthening its digital infrastructure. Analysts recommend monitoring upcoming earnings reports for further insight into the firm’s financial trajectory.
- Dyne Therapeutics (DYN): Recent SEC filing (dated 20 October 2026) disclosed that Kerr Douglas, Head of R&D and Chief Medical Officer, acquired approximately 8,000 shares under restricted stock units and exercised an option for about 12,000 shares. Post‑transaction ownership totals roughly 170,000 shares. The filing did not indicate an immediate impact on trading activity.
- Denali Therapeutics (DNLI): The company will release its third‑quarter 2026 financial results and business highlights on 3 November 2026. A conference call and webcast are scheduled for 4:30 p.m. Eastern Time, with a replay available for a limited period.
Company Overview
TransMedics Group Inc. is a biotechnology company that develops transplant therapies for patients with end‑stage organ failure. The company focuses on improving outcomes for heart, lung, and liver transplant recipients in the United States.
